Literature DB >> 36035545

Considerations for Laboratory Biosafety and Biosecurity During the Coronavirus Disease 2019 Pandemic: Applying the ISO 35001:2019 Standard and High-Reliability Organizations Principles.

Donald R Callihan1, Marian Downing2, Esmeralda Meyer3, Luis Alberto Ochoa4, Brian Petuch5, Paul Tranchell6, David White7.   

Abstract

Background: Risk assessment is a critical tool for evaluating emerging pathogens such as severe acute respiratory syndrome coronavirus 2 because of the limited available information about pathogens and the diseases they cause. Industries adopt unique frameworks for risk assessment, for example, the ISO 35001:2019 biorisk management for laboratories and other related organizations provide tools to identify, assess, control, and monitor risks associated with hazardous biological materials. Industries such as aerospace are known as high-reliability organizations (HROs) because these must balance high-risk operations with minimal catastrophic outcomes. HROs focus on five core principles: preoccupation with failure, reluctance to simplify, sensitivity to operations, resilience, and deference to expertise to evaluate and manage risk.
Results: In the present discussion, practices described in the ISO 35001 standard and the HRO model are applied to the current challenges faced by laboratories worldwide. Laboratories processing known or unknown coronavirus disease 2019 (COVID-19) samples, testing COVID-19 vaccine candidates, propagating severe acute respiratory syndrome-associated coronavirus-2, or validating diagnostic assays benefit from implementing such practices. Principles extrapolated from the HRO also help illustrate the importance of the end-to-end processes to ensure successful outcomes. Summary: Workplace safety is enhanced by the involvement of all stakeholders, from top leadership to front-line workers. High-quality outcomes as measured by a lack of incidents, accidents, injuries, or near misses are the positive consequences of strictly following standard operating procedures and timely communication of risks and pitfalls. Adopting a systematic framework to identify and manage risks posed by emerging pathogens results in increased workplace safety and higher quality processes and products. Copyright 2021, ABSA International 2021.

Entities:  

Keywords:  APHL Competency Guidelines; CWA 15793:2011; ISO 35001:2019; SARS-CoV-2/COVID-19; biorisk management

Year:  2021        PMID: 36035545      PMCID: PMC9134335          DOI: 10.1089/apb.20.0068

Source DB:  PubMed          Journal:  Appl Biosaf        ISSN: 1535-6760


  5 in total

1.  Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories.

Authors:  J Ezzelle; I R Rodriguez-Chavez; J M Darden; M Stirewalt; N Kunwar; R Hitchcock; T Walter; M P D'Souza
Journal:  J Pharm Biomed Anal       Date:  2007-10-13       Impact factor: 3.935

2.  Competency Guidelines for Public Health Laboratory Professionals: CDC and the Association of Public Health Laboratories.

Authors:  Renée Ned-Sykes; Catherine Johnson; John C Ridderhof; Eva Perlman; Anne Pollock; John M DeBoy
Journal:  MMWR Suppl       Date:  2015-05-15

3.  Summary statement of the Asilomar conference on recombinant DNA molecules.

Authors:  P Berg; D Baltimore; S Brenner; R O Roblin; M F Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1975-06       Impact factor: 11.205

4.  Implementing a quality management system using good clinical laboratory practice guidelines at KEMRI-CMR to support medical research.

Authors:  Horace Gumba; Joseph Waichungo; Brett Lowe; Alfred Mwanzu; Robert Musyimi; Johnstone Thitiri; Caroline Tigoi; Martin Kamui; James A Berkley; Ronald Ngetich; Susan Kavai; Samuel Kariuki
Journal:  Wellcome Open Res       Date:  2019-06-25

Review 5.  The genetic sequence, origin, and diagnosis of SARS-CoV-2.

Authors:  Huihui Wang; Xuemei Li; Tao Li; Shubing Zhang; Lianzi Wang; Xian Wu; Jiaqing Liu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-04-24       Impact factor: 3.267

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.